论文部分内容阅读
目的探讨经静脉注射移植同种异体骨髓来源间充质干细胞(MSC)修复损伤心肌是否可行和安全,观察移植MSC在宿主的归巢与组织学分布。方法雄性Wistar大鼠30只,分为正常大鼠MSC移植组,急性心肌梗死MSC移植组,假手术组,每组10只。结扎冠状动脉左前降支,建立大鼠急性心肌梗死模型。体外分离纯化、扩增同种大鼠骨髓MSC,于建立心肌梗死模型24h给各组大鼠经静脉输注4’6’二乙酰基2苯基吲哚(DAPI)标记的MSC,4周后处死、摘取心脏等脏器,行组织病理切片和免疫组织化学染色。结果(1)在急性心肌梗死MSC移植组,梗死区及其周边部位可见到DAPI标记的MSC;(2)在梗死心肌周边区,移植的MSC胞浆心肌特异性蛋白肌钙蛋白I和转录因子4免疫组织化学染色阳性;(3)在各组大鼠其他脏器,移植的MSC主要分布在肺脏、脾脏和肝脏;(4)细胞移植大鼠心肌组织切片未见淋巴细胞增殖,各脏器没有肿瘤形成。结论经静脉移植的MSC可归巢至大鼠梗死心肌部位,并分化为心肌细胞表型,该方法治疗缺血性心脏病安全、可行。
Objective To investigate the feasibility and safety of transplanted allogeneic bone marrow-derived mesenchymal stem cells (MSCs) into injured myocardium after intravenous injection. The homing and histological distribution of transplanted MSCs in the host were observed. Methods Thirty male Wistar rats were randomly divided into three groups: normal rat MSC transplantation group, acute myocardial infarction MSC transplantation group and sham operation group. Ligation of left anterior descending coronary artery, the establishment of acute myocardial infarction model in rats. Isolation, purification and amplification of bone marrow MSCs from the same kind of rats were used to establish myocardial infarction models. After 4 weeks of intravenous infusion of 4’6 ’diacetyl 2-phenylindole (DAPI) labeled MSCs, Sacrificed, heart and other organs removed, line histopathological and immunohistochemical staining. Results (1) DAPI-labeled MSCs could be seen in the infarcted area and the infarcted area in the acute myocardial infarction (MSC) transplantation group. (2) In the infarcted myocardium, the transplanted MSC specific protein troponin I and transcription factor 4 immunohistochemical staining positive; (3) in other organs in each group, transplanted MSC are mainly distributed in the lung, spleen and liver; (4) cell transplantation rat myocardial tissue sections no lymphocyte proliferation, No tumor formation. Conclusion The transplanted MSCs can be homing to the infarcted myocardium and differentiate into the cardiomyocyte phenotype. This method is safe and feasible for the treatment of ischemic heart disease.